Matches in Wikidata for { <http://www.wikidata.org/entity/Q83807240> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q83807240 description "clinical trial" @default.
- Q83807240 description "ensayu clínicu" @default.
- Q83807240 description "klinisch onderzoek" @default.
- Q83807240 description "клінічне випробування" @default.
- Q83807240 name "A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors" @default.
- Q83807240 name "A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors" @default.
- Q83807240 type Item @default.
- Q83807240 label "A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors" @default.
- Q83807240 label "A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors" @default.
- Q83807240 prefLabel "A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors" @default.
- Q83807240 prefLabel "A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors" @default.
- Q83807240 P1132 Q83807240-B451A12F-DD72-4C2C-B303-00DC7C8EC34A @default.
- Q83807240 P1476 Q83807240-BEA89A83-0D4F-442E-A631-4511AAFCCED5 @default.
- Q83807240 P17 Q83807240-20E68890-C54A-4B75-8B77-ED55109CB9A7 @default.
- Q83807240 P17 Q83807240-23E95CC6-198D-43DC-9F16-6A4D9E4DF08C @default.
- Q83807240 P17 Q83807240-81C2574A-E594-4A08-8482-6A8DE3CCEB9B @default.
- Q83807240 P17 Q83807240-8AF090A2-B33F-4A41-B18D-15E964D0694E @default.
- Q83807240 P17 Q83807240-9BA6B6D1-8B7A-45A7-BD32-A031002992BD @default.
- Q83807240 P3098 Q83807240-C355A5F9-A448-4238-B0E9-8187DF2620A4 @default.
- Q83807240 P31 Q83807240-08F8E7CD-06AA-4EE2-B2D3-02063EE648D5 @default.
- Q83807240 P4135 Q83807240-DF2318C4-C8A5-4F6E-8B5B-19D3B36D5D73 @default.
- Q83807240 P4844 Q83807240-A84FAB7A-2595-4CAD-9566-92E4D7C4A684 @default.
- Q83807240 P580 Q83807240-8E3E7E08-81F1-4922-93AC-9D74411B8EB7 @default.
- Q83807240 P582 Q83807240-4D9DB1F1-7185-4D62-A753-27878E4E0F8B @default.
- Q83807240 P6099 Q83807240-226C74A1-7734-4DBB-9DF8-5F40E7023195 @default.
- Q83807240 P8363 Q83807240-C2D75733-E2E5-4F8E-99D3-CF4410C96747 @default.
- Q83807240 P921 Q83807240-CA1CC0D2-B54B-4103-AEFC-A60B9095599A @default.
- Q83807240 P1132 "+60" @default.
- Q83807240 P1476 "A Phase 1b Dose Escalation Study of Abemaciclib in Combination With Temozolomide and Irinotecan (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors" @default.
- Q83807240 P17 Q142 @default.
- Q83807240 P17 Q183 @default.
- Q83807240 P17 Q29 @default.
- Q83807240 P17 Q31 @default.
- Q83807240 P17 Q38 @default.
- Q83807240 P3098 "NCT04238819" @default.
- Q83807240 P31 Q30612 @default.
- Q83807240 P4135 "+18" @default.
- Q83807240 P4844 Q412197 @default.
- Q83807240 P580 "2020-05-15T00:00:00Z" @default.
- Q83807240 P582 "2022-02-17T00:00:00Z" @default.
- Q83807240 P6099 Q5452194 @default.
- Q83807240 P8363 Q78089383 @default.
- Q83807240 P921 Q1365309 @default.